Enalapril maleate 7.5 mg once daily), bronchial asthma for the last 3 years (treated with inhaled Ipratropium bromide, Salbutamol, and long-acting Theophylline 400 mg once daily), osteoarthritis of the left knee (treated with tablet Tramadol 50 mg 3 times daily), and asymptomatic ventricular premature contractions (no active intervention) for the last 1½ years. Baseline cardiovascular parameters 3 months prior to evaluation were available: heart rate, 88/minute with occasional ectopic beats; blood pressure, 158/94 mm Hg in right upper limb; echocardiography, left ventricular diastolic dysfunction; and Holter, multiple ventricular premature contractions. The baseline ECG recording showed a pulse rate of 81/minute, PR interval of 160 msec, QRS of 120 msec, and corrected QT (QTc) of 418 msec. We started her on Olanzapine 2.5 mg (half-tablet) once daily. Follow-up at 1 week showed improvement in her psychotic features. An ECG recording showed a pulse rate of 107/minute, PR interval of 160 msec, QRS of 100 msec, and QTc of 428 msec. Olanzapine was immediately discontinued; all other treatment parameters were unchanged. A repeat ECG recorded 2 days after discontinuation showed pulse rate of 115/minute, PR interval of 200 msec, QRS of 80 msec, and QTc of 444 msec. A final ECG, recorded 1 week after discontinuation (to ensure complete washout of olanzapine from her body), showed pulse rate of 100/minute, PR interval of 160 msec, QRS of 72 msec, and QTc of 413 msec.
Recently, an increasing number of noncardiac drugs have been reported to be associated with QT interval prolongation and torsades de pointes (1) . The degree of QT interval prolongation increases in the presence of organic heart disease and sinus bradycardia, especially in female subjects (1) . Among noncardiac drugs, new (atypical) antipsychotics can cause QT interval prolongation and potentially fatal arrhythmias (2) . Sertindole (1) and risperidone (3) have been implicated to a greater degree than have clozapine or olanzapine. However, animal models have suggested that all atypical antipsychotics, including olanzapine, prolong QT interval in a concentration-dependent manner (4) . Our case demonstrates a temporal relation of QT prolongation (although in the normal range) with initiation of olanzapine and reversal of this QTc prolongation to baseline level on washout of olanzapine from the body.
One may argue that the ECG recording made just prior to discontinuation of olanzapine showed less prolongation of QTc interval, compared with the ECG recording on day 2 of discontinuation. This can be explained by olanzapine's pharmacokinetic profile (that is, its halflife of approximately 30 hours). Additionally, with regard to effects on the cardiovascular system, the patient's relatively long-term concomitant use of multiple other medicines is not associated with any significant pharmacokinetic or pharmacodynamic interactions with olanzapine (5) . Owing to ethical issues and because informed consent was not available, we did not attempt rechallenge.
Hence, based on the available information, it can be theorized that olanzapine led to QTc interval prolongation in an elderly woman with preexisting heart disease; that is, olanzapine can be a proarrythmic noncardiac agent. We recommend that atypical antipsychotics, including olanzapine, should be initiated with caution and with careful monitoring of the cardiac parameters in elderly patients.
Nitin Gupta, MD Pankaj Malhotra, MD Chandigarh, India
Respiratory Symptoms in Nocturnal Panic Attacks
Dear Editor:
There is a connection between respiratory system dysfunction and panic disorder (1). Subjects with panic disorder and respiratory problems appear as a distinct subtype: nocturnal panic attacks present with a closer relation to the respiratory system (2) . We describe 2 clinical cases of panic disorders (diagnosed according to DSM-IV criteria) with prominent respiratory symptoms during nocturnal panic attacks. Both were treated at the Laboratory of Panic and Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro.
Case Report 1
Ms A is a 42-year-old Caucasian who, while awake, had spontaneous attacks with palpitations, shortness of breath, choking, chest pain, dizziness, and fear of losing control. All laboratory tests were within the normal range. She then developed panic attacks during sleep that were associated with her waking attacks. Her nocturnal panic attacks were more intense, occurred every night, and were accompanied by prominent respiratory symptoms (that is, shortness of breath, chest pain, tingling, severe choking, and fear of losing control and dying). An agoraphobic pattern developed, and she could only sleep seated. She presented an intense anticipatory anxiety at nightfall. Her waking panic attacks changed from a spontaneous pattern to situational attacks with nausea, diarrhoea, dizziness, and tachycardia.
She was initially treated with nortriptyline 10 mg daily. At the dosage of 75 mg daily, her nocturnal panic attacks remitted, but she was still presenting limited symptom attacks. At 100 mg daily, her panic attacks fully remitted.
Case Report 2
Mr BN is a 24-year-old Caucasian with a chief complaint of choking and shortness of breath while sleeping. He presented panic attacks during sleep, with shortness of breath, chest pain, dyspnea, choking, paresthesias, sweating, tachycardia, and severe fear of dying. His laboratory tests were within normal limits. His clinical picture was marked by intense fear of having a panic attack while sleeping. He developed an avoidant pattern of falling asleep while working at his usual daily activities during the night. A diurnal drowsiness resulted in difficulty in maintaining concentration.
We instituted treatment with nortriptyline, with a gradual increase of the dosage. At 20 mg daily, the patient experienced a lessening in the frequency and intensity of his panic attacks, and the respiratory symptoms remitted. A complete remission of the panic attacks, agoraphobia, and anticipatory anxiety was achieved at 75 mg daily, and the patient has been without any panic attacks at 1year follow-up.
Nocturnal panic attacks are common and often neglected. These case reports suggest major findings in regard to them: 1) the prominent respiratory symptoms; 2) the overlapping with sleep disorders symptoms; and 3) a change in the pattern of diurnal panic attacks, from spontaneous situational. A hypothesis to account for these findings exists in the pathophysiology of the sleep, when blood carbon dioxide (CO 2 ) levels rise significantly (3) . The panic disorder patients, who have heightened CO 2 sensitivity (2,3), according to Klein's false suffocation alarm theory (4), start a cycle in which enhanced CO 2 leads to more frequent sighing in an attempt to reduce arterial CO 2 levels (3).
Fabiana L Lopes, MD Isabella Nascimento, MD Alexandre M Valença, MD M<rcio Versiani, MD Antonio E Nardi, MD Rio de Janeiro, Brazil
Carbon Dioxide Test in Respiratory Panic Disorder Subtype
Inhaling high concentrations of carbon dioxide (CO 2 ) has consistently been shown to provoke panic attacks in patients with panic disorder (PD) (1). Our objective was to verify the sensitivity to CO 2 challenge of PD patients with respiratory and nonrespiratory subtypes. We randomly selected 20 PD patients (diagnosed according to DSM-IV criteria) at the Laboratory of Panic and Respiration in Rio de Janeiro. The subjects signed a voluntary written inform consent, and the protocol was approved by our local ethical committee.
To participate, we required the subjects to be at least 18 years old, to report at least 3 panic attacks in the last 2 weeks, and to be free of psychotropic drugs for at least 1 week. Exclusion criteria were any other current mental or major medical disorders, pregnancy, and substance abuse within the prior 6 months. We assessed the clinical symptoms of the most severe recent panic attack before the initial test to classify the subjects as respiratory and nonrespiratory subtypes (2) .
The test was double-blind, and 2 mixtures were used: 1) 35% CO 2 and 65% O 2 , and 2) 100% atmospheric compressed air, given 20 minutes apart. Participants were asked to exhale as fully as possible, place the mask on their face, and take a fast, vital-capacity breath, inhaling either the 35% CO 2 mixture or the atmospheric compressed air. They were asked to hold their breath for 8 seconds. Immediately after, they were asked to repeat the fast, vital-capacity breath and hold it again for 8 seconds. After 20 minutes, this test was repeated with the other gas mixture. We repeated the tests in 2 weeks. During that time, no participants received any psychotropic drugs.
We defined a CO 2 -induced panic attack as follows: 1) 4 or more DSM-IV panic attack symptoms, 2) at least 1 DSM-IV cognitive symptom (for example, fear of dying or losing control), 3) the sensation of a spontaneous panic attack, and 4) agreement of 2 investigators. To compare the differences between the presence of panic attacks after CO 2 challenge, we used Fisher's exact test.
The patients were 12 women and 8 men with a mean (SD) age of 35.8 (6.9) years. In the respiratory subtype there were 6 women and 5 men with a mean (SD) age of 33.4 (9.8) years, and in the nonrespiratory subtype there were 6 women and 3 men with a mean (SD) age of 37.8 (4.3) years. There was no difference between the 2 groups in mean age (t-test, P = 0.677).
In the first CO 2 challenge test, 7/11 (63.6%) respiratory PD patients and 3/9 (33.3%) nonrespiratory PD patients had a panic attack (Fisher's exact test, P = 0.024). In the second CO 2 challenge (after 2 weeks), 9/11 (81.8%) respiratory PD patients and 3/9 (33.3%) nonrespiratory PD patients had a panic attack (Fisher's exact test, P = 0.011). No patient had a panic attack with atmospheric air.
Our results are similar to those of Biber and Alkin (1). Klein's theory (3) could explain why the respiratory panic subtype
